^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GSK5764227
i
Other names: GSK 5764227, GSK-5764227, GSK’227, GSK5764227, HS-20093, HS20093, HS 20093
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GSK, Jiangsu Hansoh Pharma
Drug class:
Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
Related drugs:
18d
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
P2, N=218, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P2 trial
|
abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • GSK5764227
25d
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=158, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Aug 2027 | Trial primary completion date: Sep 2028 --> Aug 2027
Trial completion date • Trial primary completion date
|
Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • GSK5764227 • nelistotug (GSK6097608)
2ms
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial
|
itraconazole • GSK5764227
4ms
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P3, N=300, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
Enrollment open
|
topotecan • GSK5764227
4ms
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=63, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial
|
GSK5764227 • HRS-5041
4ms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (clinicaltrials.gov)
P1/2, N=320, Recruiting, GlaxoSmithKline | N=200 --> 320 | Trial completion date: Feb 2028 --> Jun 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
Enrollment change • Trial completion date • Trial primary completion date
|
GSK5764227
4ms
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P3, N=300, Not yet recruiting, GlaxoSmithKline
New P3 trial
|
topotecan • GSK5764227
5ms
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Shanghai Hansoh Biomedical Co., Ltd
New P1 trial
|
AiRuiLi (adebrelimab) • GSK5764227
5ms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (clinicaltrials.gov)
P1/2, N=200, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | N=120 --> 200
Enrollment open • Enrollment change
|
GSK5764227
6ms
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=157, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Avastin (bevacizumab) • docetaxel • AiTan (rivoceranib) • albumin-bound paclitaxel • irinotecan • GSK5733584 • GSK5764227 • HS-10502
7ms
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=762, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
New P1 trial
|
cisplatin • carboplatin • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • AiRuiLi (adebrelimab) • GSK5764227 • HS-10370 • PM1080
8ms
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure (clinicaltrials.gov)
P3, N=117, Not yet recruiting, Hansoh BioMedical R&D Company
New P3 trial
|
gemcitabine • docetaxel • GSK5764227
Share via
